In situ artificial membrane permeation assay under hydrodynamic control: permeability-pH profiles of warfarin and verapamil.
OBJECTIVE
To investigate the permeation of two ionisable drug molecules, warfarin and verapamil, across artificial membranes. For the first time since the introduction of the parallel artificial membrane permeation assay (PAMPA) in 1998, in situ permeation-time profiles of drug molecules are studied.


METHODS
The method employs a rotating-diffusion cell where the donor and acceptor compartments are separated by a lipid-impregnated artificial membrane. The permeation of the solute is investigated under well-defined hydrodynamic conditions with control over the unstirred water layer. The flux of the permeating molecule is analysed in situ using UV spectrophotometry.


RESULTS
In situ permeation-time profiles are obtained under hydrodynamic control and used to determine permeability coefficients. An advanced analytical transport model is derived to account for the membrane retention, two-way flux and pH gradient between the two compartments. Moreover, a numerical permeation model was developed to rationalise the time-dependent permeation profiles. The membrane permeability, intrinsic permeability and unstirred water permeability coefficients of two drug molecules are obtained from two independent methods, hydrodynamic extrapolation and pH profiling, and the results are compared.


CONCLUSIONS
Both warfarin and verapamil exhibit high permeability values, which is consistent with the high fraction absorbed in human. Our results demonstrate that a considerable lag-time, varying with the solute lipophilicity and stirring rate, exists in membrane permeation and leads to incorrect compound ranking if it is not treated properly. Comparison of the permeability data as a function of pH and stirring rate suggests that some transport of the ionized molecules occurs, most likely via ion-pairing.
Velický
Matej
M
School of Chemistry, University of Manchester, Oxford Road, Manchester, M13 9PL, UK.
Bradley
Dan F
DF
Tam
Kin Y
KY
Dryfe
Robert A W
RA
D000925:Anticoagulants / Q000493:pharmacokinetics*; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008567:Membranes, Artificial; D046210:Microfluidic Analytical Techniques / Q000379:methods; D044085:Microfluidics; D008954:Models, Biological; D010539:Permeability; D013997:Time Factors; D014700:Verapamil / Q000493:pharmacokinetics*; D014859:Warfarin / Q000493:pharmacokinetics*
D000925:Anticoagulants; D002121:Calcium Channel Blockers; D008567:Membranes, Artificial; D014859:Warfarin; D014700:Verapamil
J Pharm Sci. 1995 Oct;84(10):1197-204
8801334
Pharm Res. 2008 Jul;25(7):1511-20
18185985
Int J Pharm. 2002 Jul 25;241(2):241-51
12100852
Drug Metab Dispos. 2008 Jul;36(7):1385-405
18426954
J Pharm Sci. 2007 Nov;96(11):2886-92
17694546
J Med Chem. 2005 Apr 7;48(7):2571-6
15801846
Eur J Pharm Sci. 2007 Mar;30(3-4):324-32
17204409
J Med Chem. 1998 Mar 26;41(7):1007-10
9544199
Int J Pharm. 2001 Oct 9;228(1-2):181-8
11576780
Pharm Res. 1999 Oct;16(10):1633-8
10554109
J Pharm Sci. 1982 Jan;71(1):77-84
7057387
Biochem Biophys Res Commun. 1991 Mar 29;175(3):880-5
1673839
J Pharm Sci. 1998 Dec;87(12):1604-7
10189274
J Pharmacol Exp Ther. 1957 Mar;119(3):361-9
13417090
Pharm Res. 1989 Sep;6(9):743-7
2682590
Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):325-42
16922646
Pharm Res. 1999 Jun;16(6):882-8
10397609
J Med Chem. 2001 Mar 15;44(6):923-30
11300874
Eur J Pharm Sci. 2001 Dec;14(4):271-80
11684401
Eur J Pharm Sci. 2004 Aug;22(5):365-74
15265506
J Pharm Sci. 2002 Mar;91(3):640-6
11920749
J Pharm Pharmacol. 2004 Jun;56(6):717-24
15231036
Eur J Med Chem. 2003 Mar;38(3):223-32
12667689
Biophys Chem. 2007 Sep;129(2-3):120-5
17566633
Eur J Pharm Sci. 2006 Jan;27(1):80-90
16246536
Int J Pharm. 2003 May 12;257(1-2):245-51
12711179
J Pharm Sci. 1998 Apr;87(4):403-10
9548891
Eur J Pharm Sci. 2006 Nov;29(3-4):259-68
16781125
Eur J Pharm Sci. 2004 Mar;21(4):429-41
14998573
J Pharm Sci. 2007 Nov;96(11):2893-909
17803196
J Pharm Sci. 1986 Dec;75(12):1157-61
3559925
Eur J Pharm Sci. 2004 Sep;23(1):13-47
15324921
Eur J Pharm Sci. 2005 Mar;24(4):333-49
15734300
J Pharm Sci. 1999 Jan;88(1):28-33
9874698
Eur J Pharm Sci. 2006 Jul;28(4):336-43
16697561
J Chromatogr A. 2006 Aug 18;1124(1-2):29-34
16696986
Analyst. 2008 May;133(5):655-9
18427688